An open-label, non-randomized, biopsy-based mechanistic study on pharmacokinetics, pharmacodynamics, safety and tolerability of ianalumab in patients with Sjögren's syndrome
CompletedCTIS2023-508957-24-00
Novartis Pharma AGSjögren's syndrome
Start: 2022-07-27End: 2026-01-05Target: 20Updated: 2025-04-29